The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1):
“CSL Behring is pleased to inform you that we are lifting our precautionary distribution hold, and ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] is now available for our customers.
“With this release of ZEMAIRA, CSL Behring is introducing a new and improved reconstitution device called the Mix2Vial® Transfer Set.
“The Mix2Vial Transfer Set, designed for use with ZEMAIRA, improves reconstitution and streamlines Alpha-1 therapy by:
- Helps prevent vacuum loss
- Less frequent spillage
- Guided technique leading to safer handling
“Important Note: If the product comes with the Mix2Vial Transfer Set, you must only use the Mix2Vial and never use the old spike.
If you are a patient who typically self-infuses, please consult your healthcare professional.”
The original artcle can be found here: https://www.alpha1.org/Alphas-Friends-Family/Resources/News/ArtMID/5952/ArticleID/9342/Update-CSL-Behring-announcement-on-their-product-Zemaira